A prospective longitudinal observational study analysing safety and efficacy of emicizumab in haemophilia patients
Latest Information Update: 13 Oct 2021
Price :
$35 *
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2021 New trial record